Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HRS-2129 in Healthy Subjects
NCT06742840Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing HRS-2129 Experimental with Placebo Comparator (2 arms). Primary endpoint: Incidence and severity of adverse events (AEs). Started Dec 2024; status: completed.
02
Drugs
HRS-2129
03
Conditions
pain
Beyond the preview
Go deeper on NCT06742840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06742840.